Potent tropomyosin-related kinase B (TrkB) agonist (IC50 = 47 nM). Induces activation of Trk, Akt and ERK in mouse hippocampus and striatum. Reverses deficits in motor task learning in mice following traumatic brain injury; restores respiratory function in a rat model of Rett syndrome.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 339.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.95 mL||14.73 mL||29.47 mL|
|5 mM||0.59 mL||2.95 mL||5.89 mL|
|10 mM||0.29 mL||1.47 mL||2.95 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the products' biological activity.
Massa et al (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J.Clin.Invest. 120 1774 PMID: 20407211
Schmid et al (2012) A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J.Neurosci. 32 1803 PMID: 22302819
If you know of a relevant reference for LM 22A4, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: LM 22A4, supplier, LM22A4, tropomyosin, related, kinases, B, TrkB, agonists, potent, Rett, syndrome, Trk, Receptors, Trk, Receptors, Tocris Bioscience
1 Citation for LM 22A4
Citations are publications that use Tocris products. Selected citations for LM 22A4 include:
Al-Qudah et al (2014) Brain-derived neurotrophic factor enhances cholinergic contraction of longitudinal muscle of rabbit intestine via activation of phospholipase C. Am J Physiol Gastrointest Liver Physiol 306 G328 PMID: 24356881
Do you know of a great paper that uses LM 22A4 from Tocris? If so please let us know.
Reviews for LM 22A4
There are currently no reviews for this product. Be the first to review LM 22A4 and earn rewards!
Have you used LM 22A4?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.